Open Access Full Text Article

RETRACTION

microRNA-612 Suppresses the Malignant Development of Non-Small-Cell Lung Cancer by Directly Targeting Bromodomain-Containing Protein 4 [Retraction]

Kang X, Kong F, Wu S, et al. *Onco Targets Ther*. 2019;12:4167–4179.

The Editor and Publisher of *OncoTargets and Therapy* wish to retract the published article. Concerns were raised regarded the alleged duplication of images in Figures 5C and 8A with similar images from unrelated articles, specifically:

- Figure 5C, panel A549 BRD4 siRNA appears to have been duplicated with a similar image in Figure 2D, panel H522 miR-802 mimics from Zhang et al, 2019 (https://doi.org/10.3892/ijo.2019.4765).
- Figure 5C panels H522 and A549; NC siRNA, BRD4 siRNA appear to have been duplicated with similar images in Figures 2D, panel pcDNA3.1; pHAND2-AS1 and 3D panels si-NC; siHAND2-AS1 from Yu et al, 2020 (https://doi.org/10.2147/OTT.S233256).

Figure 8A, agomir-NC appears to have been duplicated with a similar image in Figure 8A, NC mimics from Yun et al, 2019 (<u>https://doi.org/10.2147/CMAR.</u><u>S198615</u>).

The authors responded to our queries but were unable to provide an explanation for the alleged image duplication and could not provide the original raw data for their study and have therefore agreed to retract the article.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

agents and protocols on patient perspectives such as quality of life,

adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/

testimonials.php to read real quotes from published authors.

OncoTargets and Therapy

Dovepress

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

https://doi.org/10.2147/OTT.\$337587

Received: 3 September 2021 Accepted: 3 September 2021 Published: 9 September 2021

OncoTargets and Therapy 2021:14 4745

4745

© 2021 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. for permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).